cystic fibrosis

Oral lenabasum failed to significantly reduce the frequency of pulmonary exacerbations in people with cystic fibrosis (CF) treated in a Phase 2 trial, but new analyses suggest this failure could be attributed, at least in part, to differences among the patients that confounded results. The investigational therapy showed some…

Eloxx Pharmaceuticals presented preclinical safety and efficacy data supporting ELX-02, its investigational treatment for cystic fibrosis (CF) caused by nonsense mutations that is also being evaluated in two enrolling, Phase 2 trials. The data were presented as two posters at this year’s virtual North American Cystic Fibrosis…

The National Board for Respiratory Care (NBRC) has launched “CHOOSE ONE: Every Breath Counts Campaign,” a fundraising initiative intended to protect and improve the lives of people who need respiratory care, such as those with lung diseases like cystic fibrosis (CF). This year, more than $200,000 will…

The Cystic Fibrosis Foundation (CFF) is awarding Synspira Therapeutics up to $14 million in additional funding to support the development of two therapies to address complications of cystic fibrosis (CF), namely malabsorption and pulmonary infections. “Despite the approval of new treatments for the underlying cause of CF, many…

Inhaled tobramycin alone works as well at eradicating an initial infection by Pseudomonas aeruginosa bacteria in people with cystic fibrosis (CF), and its use in combination with an oral fluoroquinolone, such as ciprofloxacin or levofloxacin, appears to be redundant, a small study reported. Its results also suggest that inhaled…

The U.S. Food and Drug Administration (FDA) cleared Armata Pharmaceuticals‘ investigational new drug (IND) application for a Phase 1b/2a clinical trial of AP-PA02 for the treatment of the Pseudomonas aeruginosa bacterial infections that are a hallmark of cystic fibrosis (CF). “We are very pleased…

A Phase 2 clinical trial investigating MS1819 in combination with stable pancreatic enzyme replacement therapy (PERT) to treat exocrine pancreatic insufficiency (EPI) in people with cystic fibrosis (CF) is actively recruiting participants in Europe, AzurRx BioPharma, the treatment’s developer, announced. The open-label study (NCT04302662) expects to enroll 24 CF patients, ages 12…

Ionis Pharmaceuticals’ investigational inhaled therapy IONIS-ENAC-2.5Rx showed promise in a Phase 1/2a study as a potential new treatment for cystic fibrosis (CF), the company announced, citing trial data. That clinical data showed that ENAC-2.5Rx led to a reduction in the expression of ENaC, a sodium transport…

Medicine by Design, which supports work in regenerative medicines, gave a 2020 New Ideas Awards to support a researcher exploring an alternative pathway to the CFTR protein as a possible treatment for cystic fibrosis (CF). The awardee, Amy Wong, PhD, works in developmental and stem cell biology at the…

A Phase 1b clinical trial evaluating Calithera Biosciences’ investigational oral therapy CB-280 is recruiting adults with cystic fibrosis (CF) and chronic airway infections at several U.S. sites. The trial’s design, along with CB-280’s preclinical data, was presented by Joel D. Mermis, MD, of the University…